E1 ReplicatedModerate confidencePEM not requiredRCTPeer-reviewedMachine draft
Standard · 3 min
L-carnitine decreases severity and type of fatigue induced by interferon-alpha in the treatment of patients with hepatitis C.
Neri, Sergio, Pistone, Giovanni, Saraceno, Barbara et al. · Neuropsychobiology · 2003 · DOI
Quick Summary
This study tested whether a supplement called L-carnitine could reduce fatigue caused by interferon-alpha treatment in people with hepatitis C. Fifty patients received either interferon alone or interferon plus L-carnitine daily. Patients taking the supplement experienced significantly less physical and mental fatigue, and their fatigue was less severe, particularly in the first three months of treatment.
Why It Matters
This study is relevant to ME/CFS research because fatigue is the hallmark symptom and the mechanisms underlying interferon-induced fatigue may overlap with ME/CFS pathophysiology, including potential mitochondrial dysfunction and carnitine deficiency. The finding that L-carnitine substantially reduces fatigue severity and type suggests it warrants investigation as a potential therapeutic intervention in ME/CFS populations.
Observed Findings
Physical fatigue significantly decreased in the carnitine group at 1 month (p<0.01) and 3 months (p<0.01) compared to interferon-only group
Mental fatigue showed significant reduction in the carnitine group at 1 month (p<0.01)
Fatigue severity was markedly less in the carnitine group at 1 and 3 months (p<0.0005)
Interferon monotherapy induced fatigue in the majority of patients at months 1 and 3, with values decreasing by month 6
Patients receiving carnitine showed early and sustained reduction of fatigue levels across the study period
Inferred Conclusions
L-carnitine supplementation significantly mitigates both physical and mental fatigue induced by interferon-alpha treatment
Carnitine may provide an enhanced energetic substrate that improves tolerance to interferon-related side effects
The effect appears early (within 1 month) and persists through the first 3 months of therapy
Abnormalities in neurotransmission, particularly serotonin dysfunction, may be involved in both fatigue and depression in chronic disease
Remaining Questions
What is the mechanism by which L-carnitine reduces interferon-induced fatigue? Is carnitine deficiency present in hepatitis C patients, and does supplementation correct this deficiency?
What This Study Does Not Prove
This study does not prove that L-carnitine will be effective in ME/CFS patients, as interferon-induced fatigue and ME/CFS have different etiologies. It does not establish whether carnitine deficiency is present in ME/CFS or that the mechanism of carnitine benefit in hepatitis C applies to idiopathic fatigue syndromes. Correlation between carnitine supplementation and fatigue reduction does not prove causation or identify the biological mechanism involved.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →